Neuraxis (NRXS) Accounts Payables (2022 - 2025)
Neuraxis (NRXS) posted Accounts Payables of $28660.0 for Q4 2025, down 96.77% sequentially from $886399.0 in Q3 2025, and down 95.2% YoY from $596946.0 in Q4 2024.
Neuraxis (NRXS) Accounts Payables (2022 - 2025) Analysis & Trends
Neuraxis has reported Accounts Payables for 4 years, with the latest figure at $28660.0 in Q4 2025.
- Quarterly Accounts Payables fell 95.2% year-over-year to $28660.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $28660.0 (down 95.2% YoY) and the FY2025 annual result came in at $28660.0, down 95.2% from the prior year.
- Accounts Payables retreated to $28660.0 in Q4 2025 per NRXS's latest filing, from $886399.0 in the prior quarter.
- Over five years, Accounts Payables peaked at $1.2 million in Q1 2024 and troughed at $28660.0 in Q4 2025.
- A 4-year average of $487313.2 and a median of $274515.0 in 2024 frame the typical range for Accounts Payables.
- The sharpest annual moves came in 2023 and 2025: Accounts Payables surged 1935.05% in 2023, then slumped 96.95% in 2025.
- Over 4 years, Accounts Payables stood at $59174.0 in 2022, then soared by 1935.05% to $1.2 million in 2023, then plunged by 50.43% to $596946.0 in 2024, then slumped by 95.2% to $28660.0 in 2025.
- According to Business Quant data, Accounts Payables over the past three periods registered $28660.0, $886399.0, and $464518.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Neuraxis | 74.54 Mn | 66.21 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 28,660.00 |
| Sep 30, 2025 | 886,399.00 |
| Jun 30, 2025 | 464,518.00 |
| Mar 31, 2025 | 37,684.00 |
| Dec 31, 2024 | 596,946.00 |
| Sep 30, 2024 | 84,512.00 |
| Jun 30, 2024 | 1.12 Mn |
| Mar 31, 2024 | 1.24 Mn |
| Dec 31, 2023 | 1.20 Mn |
| Sep 30, 2023 | 68,972.00 |
| Jun 30, 2023 | 61,317.00 |
| Dec 31, 2022 | 59,174.00 |